Protein kinase targeted therapeutics
The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and/or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a protein kinase inhibitor,
wherein said protein kinase inhibitor inhibits one or more of p38 MAPK, JNK, ERK, and CK1δ,
wherein said protein kinase inhibitor is described by the following formula:
including salts and both R and S enantiomeric forms and racemic mixtures thereof;
wherein R1 and R2 are independently selected from i) R1 is H and R2 is CH3, or ii) R1 is CH3 and R2 is H;
wherein R3 is selected from H, CH3,
naphthalene,
wherein R5 is H, CH3, a linear or branched, saturated or unsaturated, a substituted or unsubstituted, aliphatic chain having less than 5 carbons; and
wherein R7 is selected from the group consisting of H, CH3,
naphthalene,
2. The pharmaceutical composition of claim 1 , wherein said compound is: